GSE164492 KSR1 knockdown 2 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE164492_KSR1 knockdown_2_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE164492_KSR1 knockdown_2_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE164492_KSR1 knockdown_2_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE164492_KSR1 knockdown_2_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

acetylserotonin O-methyltransferase like

Gene

valyl-tRNA synthetase 1

Gene

MT-CO2 pseudogene 12

Gene

brain cytoplasmic RNA 1

Gene

RNA component of 7SK nuclear ribonucleoprotein

Gene

RNA component of signal recognition particle 7SL2

Gene

ATP5MF-PTCD1 readthrough

Gene

PHLDA1 antisense RNA 1

Gene

RNA component of signal recognition particle 7SL1

Gene

H2A clustered histone 18

  • Gene

    acetylserotonin O-methyltransferase like


  • Gene

    valyl-tRNA synthetase 1


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    brain cytoplasmic RNA 1


  • Gene

    RNA component of 7SK nuclear ribonucleoprotein


  • Gene

    RNA component of signal recognition particle 7SL2


  • Gene

    ATP5MF-PTCD1 readthrough


  • Gene

    PHLDA1 antisense RNA 1


  • Gene

    RNA component of signal recognition particle 7SL1


  • Gene

    H2A clustered histone 18

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.